Cardiocomm Solutions (EKGGF) 0.0830 $EKGGF
CardioComm Solutions Announces Issuance of Stock Options and Shares
ACCESSWIRE - Fri Apr 11, 4:04PM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 11, 2014 / CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that it has granted an aggregate of 500,060 incentive stock options. 250,060 options have been granted to Mr. Etienne Grima, the Company's Chief Executive Officer, and 250,000 options have been granted to a contractor of the Company. The 500,060 options issued are exercisable at $0.144 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.
CardioComm Solutions Announces Release of GEMSTM Windows 7 Compatible, Remote Patient Monitoring Technology
ACCESSWIRE - Fri Mar 28, 9:01AM CDT
CardioComm Solutions to begin immediate rollout of GEMSTM for Windows 7 remote ECG analysis, data management software to extensive base of current US health care providers and customers.
Single Tranche Sale of CardioComm Solutions, Shares Completed
ACCESSWIRE - Wed Mar 26, 12:39PM CDT
Press release disseminated on behalf of Anatoly Langer
FDA Clears CardioComm Solutions' GUAVA II ECG Viewer with ECG Acquisition, Analysis, Interpretation, and Reporting Capabilities as a Class II Medical Device
ACCESSWIRE - Tue Feb 25, 7:47AM CST
GUAVA II offers regulatory credibility and efficiency to ECG reading services for physicians and hospitals
CardioComm Solutions Issues Stock Options
ACCESSWIRE - Thu Feb 20, 6:07PM CST
TORONTO, ONTARIO, February 20, 2014 - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" today announced that an aggregate of 567,460 incentive stock options have been granted to two directors of the Company and to a contractor of the Company. The 417,460 options issued to the directors are exercisable at $0.18 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The 150,000 options issued to the contractor are exercisable at $0.15 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.
CardioComm Solutions Completes Technology Pilot in the Long-Term Patient Care Market with the HeartCheck(tm) ECG Monitor and SMART Monitoring ECG Service Technologies
ACCESSWIRE - Fri Feb 07, 8:25AM CST
Arrhythmia Surveillance Utilized HeartCheck(TM) Device and SMART Monitoring ECG Service Technologies
CardioComm Solutions Closes Second Tranche of Equity Financing; Company Remains on Track to Complete $1 Million in Financing in Q1 2014
ACCESSWIRE - Fri Jan 31, 8:01AM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" announced today it has closed the second tranche of its previously announced private placement equity financing. Under the financing, the Company issued 2,648,000 units at a price of $0.0675 per unit, for gross proceeds of $178,740. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.10. For further information regarding the financing, please see the Company's press release that was issued on January 9, 2014. The gross proceeds from the financing will be used for general working capital of the Company. The shares and warrants issued by the Company are subject to a four month hold period which expires on May 31, 2014. The Company also confirmed that it will continue its current private placement equity financing offer.
CardioComm Solutions Executes Distribution and Co-Marketing Agreement to Promote HeartCheck(tm) PEN Sales and SMART Monitoring Services. SMART Monitoring Integration of Reka ECG...
ACCESSWIRE - Thu Jan 23, 4:08PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" today announced that it has completed a HeartCheck(TM) and SMART Monitoring distribution and co-marketing agreement ("Agreement" with Reka Health, Inc. (REKA), a US based company. REKA will promote sales of the HeartCheck(TM) PEN through their own, proprietary international distribution channels, including US-based accountable care organization ("ACO" patient portals.
CardioComm Solutions Issues Correction with Respect to Closing First Tranche of Financing
ACCESSWIRE - Wed Jan 22, 6:19PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" today issued the following correction to its press release dated January 21, 2014 respecting the closing of the first tranche of its ongoing private placement equity financing: Please note that in the first tranche the Company issued 1,622,222 units at a price of $0.0675 per unit, for gross proceeds of $109,500.
CardioComm Solutions Secures $500,000 in GEMS(tm) 4 and GUAVA Software License Agreement. Licensing Deal Signals the Start of Sales of Windows 7 Compatible ECG Software Solutions
ACCESSWIRE - Wed Jan 22, 2:55PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" today announced that it has completed a software and source code licensing agreement ("SLA" for use of the Company's proprietary Global ECG Management Solution ("GEMS(TM)" and GUAVA ECG viewer by MD Primer Inc. ("MDP" . MDP is a clinical research and education organization enabling improvement in patient care through innovation. MDP is under the direction of Dr. Anatoly Langer, CardioComm Solutions' Chairman. As MDP is a related party of CardioComm Solutions, Dr. Langer abstained from voting on the SLA when it received board approval. The SLA is subject to approval by the TSX Venture Exchange.
CardioComm Solutions Closes First Tranche of Equity Financing. Company Plans to Complete $1 Million in Financing in Q1 2014
ACCESSWIRE - Tue Jan 21, 8:10PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" announced today it had closed the first tranche of its previously announced private placement equity financing. Under the financing, the Company issued $1,622,222 units at a price of $0.0675 per unit, for gross proceeds of $109,500. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.10. For further information regarding the financing, please see the Company's press release that was issued on January 9, 2014. The gross proceeds from the financing will be used for general working capital of the Company. The shares and warrants issued by the Company are subject to a four month hold period which expires on May 21, 2014. The Company also confirmed that it will continue its current private placement equity financing offer.
CardioComm Solutions Re-Prices Previously Announced Equity Financing
ACCESSWIRE - Thu Jan 09, 5:47PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" today announced that it has re-priced its previously announced equity financing. The Company will now be conducting a private placement equity financing under which it intends to issue 15,000,000 units at a price of $0.0675 per unit for gross proceeds of $1,012,500. Each unit will be comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.10. The securities to be issued under the financing will be subject to a four month hold period. The terms of the financing are subject to the approval of the TSX Venture Exchange.
Cardiocomm Solutions Appoints Industry Veteran As Vp Sales And Marketing To Build U.S. Based Patient Monitoring Software And Ecg Services Business
ACCESSWIRE - Wed Jan 08, 10:01AM CST
Former Executive of ScottCare, CardioNet and Lifewatch Corporation Set to Drive Sales of GEMS(TM) and Mobile Patient Monitoring Solutions into the U.S. Market
CardioComm Solutions Announces Equity Financing. Funding will be used as bridge financing to complete Q1 2014 objectives
ACCESSWIRE - Thu Dec 12, 12:53PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company" today announced that it will be conducting a non-brokered private placement equity financing under which it intends to issue between 4,166,667 to 8,333,334 units at a price of $0.12 per unit for gross proceeds of $500,000 to $1,000,000. Each unit will be comprised of one (1) common share of the Company and one (1) common share purchase warrant exercisable for two (2) years for an additional share at a price of $0.18. The securities to be issued under the financing will be subject to a four (4) month hold period. The terms of the financing are subject to the approval of the TSX Venture Exchange.
CardioComm Solutions to Offer Free SMART Monitoring ECG Readings to HeartCheck(tm) Device Owners through GEMS Home in the United States. Free Cardiac Arrhythmia Surveillance Ava...
ACCESSWIRE - Tue Dec 10, 10:37AM CST
Toronto, Canada - CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or the "Company" , a global medical provider of electrocardiogram ("ECG" acquisition and management software solutions, announced it shall be providing HeartCheckTM SMART Monitoring ECG services at no cost effective December 10, 2013 for its USA based customers who have been provided a HeartCheckTM device under a physician prescription.
Medical Electronics - Global Trends, Estimates and Forecasts, 2011-2018
M2 - Fri Dec 06, 4:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7plqm/medical) has announced the addition of the "Medical Electronics - Global Trends, Estimates and Forecasts, 2011-2018" report to their offering. The Medical Electronics Market Is Expected To Reach US$372.4 Billion By 2018. Globally, medical therapeutics and imaging systems together account for approximately 52.9% of the market and are expected to support the medical electronics industry going forward. Geographical analysis shows that the highest Compounded Annual Growth Rate (CAGR) of 17.2% is anticipated from Asia-Pacific region during the analysis period, 2011-2018. Among the application sectors, monitoring & surgical systems account for the largest share of the entire market, driving a CAGR of 13.4% during the analysis period 2011-2018. Imaging Systems see as the fastest growing application with a forecast CAGR of approximately 16.9% by 2018. Along with the fast growth and rapid advancement in technology related to healthcare industry, the medical electronics expectations have increased innovatively for large numbers of incurable disease. Publication Overview The report reviews the latest medical electronics market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for electronics sector investments. The study reveals profitable investment strategies for electronics companies, business executives, product marketing managers, new business investors and many more in preferred locations. The report primarily focuses on: - Emerging Market Trends - Advancements in the Technological Space - Market Demand of the Segments (By-Region) - Key Growth Areas and Market Size - Region-Wise Demand Factor - Key Competitors Edge - Investment Strategies More than 1346 leading market players have been identified in electronics industry. 51 key companies are profiled. Applications Covered - Monitoring & Surgical Systems - Medical Therapeutics - Imaging Systems - Diagnostics Examples of Companies Mentioned - 3M Healthcare - Abbott Vascular Devices - Baxter International - Becton, Dickinson & Co. - Blueradios - C. R. Bard - Cactus Semiconductor - Cardiocomm Solutions - Cardiomems - Digirad Corporation - Medtronic - Monebo Technologies - Novadaq Technologies - Perkinelmer - Siemens Medical Solutions - St. Jude Medical - Fukuda Denshi - Heartware - IBM - Indraprastha Apollo Hospital - Panasonic Electric Works - Microports Medical - Nihon Kohden Corporation - Covidien - Dr?ger Medical Ag & Co. - F.Hoffmann-La Roche - Ge Healthcare - Philips Medical Systems - Siemens Group - Smith & Nephew For more information visit http://www.researchandmarkets.com/research/b7plqm/medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
CardioComm Solutions' HeartCheck (tm) Technologies to be Used in Canadian Parkinson's Research Study. Second CIHR and Industry Sponsored Study to Use HeartCheck (tm) and SMART ...
ACCESSWIRE - Thu Dec 05, 3:23PM CST
Toronto, Canada - CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or the "Company" , a global medical provider of electrocardiogram ("ECG" acquisition and management software solutions, announced it shall be providing HeartCheckTM based ECG screening technologies to researchers from the Research Institute of the McGill University Health Centre (RI MUHC) and the Montreal General Hospital (Quebec, Canada). This research study, which will be funded by the Canadian Institutes of Health Research (CIHR) and the Webster Foundation, will evaluate the potential relationship between caffeine intake and improvements in motor symptoms of persons with Parkinson's disease ("PD" .
Cardiocomm Solutions Completes Mobile Cardiac Telemetry Software Release for Raytel Cardiac Services
ACCESSWIRE - Mon Nov 25, 2:17PM CST
Raytel Cardiac Services will be the first to launch into the American MCT monitoring market using the CardioComm Solutions Wireless Arrhythmia Services Software
CardioComm Solutions' GEMS Home & SMART Monitoring Technologies Expanded To Support Prescription, HeartCheckTM Handheld ECG Devices
ACCESSWIRE - Tue Nov 12, 6:32PM CST
Rapid physician ECG interpretation services now available to patients, allied health care workers and physician groups.
CardioComm Solutions' HeartCheckTM ECG Monitoring Technologies for Atrial Fibrillation Screening to be Presented at the Canadian Stroke Congress
ACCESSWIRE - Wed Sep 18, 9:18AM CDT
Results from the Heart and Stroke Foundation "Be Pulse Aware" ECG Screening Campaign will be released during Vascular 2013
CardioComm Solutions Announces Issuance of Stock Options and Shares
ACCESSWIRE - Fri Apr 11, 4:04PM CDT
TORONTO, ONTARIO / ACCESSWIRE / April 11, 2014 / CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that it has granted an aggregate of 500,060 incentive stock options. 250,060 options have been granted to Mr. Etienne Grima, the Company's Chief Executive Officer, and 250,000 options have been granted to a contractor of the Company. The 500,060 options issued are exercisable at $0.144 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws. CardioComm Solutions Announces Release of GEMSTM Windows 7 Compatible, Remote Patient Monitoring Technology
ACCESSWIRE - Fri Mar 28, 9:01AM CDT
CardioComm Solutions to begin immediate rollout of GEMSTM for Windows 7 remote ECG analysis, data management software to extensive base of current US health care providers and customers.
Single Tranche Sale of CardioComm Solutions, Shares Completed
ACCESSWIRE - Wed Mar 26, 12:39PM CDT
Press release disseminated on behalf of Anatoly Langer
FDA Clears CardioComm Solutions' GUAVA II ECG Viewer with ECG Acquisition, Analysis, Interpretation, and Reporting Capabilities as a Class II Medical Device
ACCESSWIRE - Tue Feb 25, 7:47AM CST
GUAVA II offers regulatory credibility and efficiency to ECG reading services for physicians and hospitals
CardioComm Solutions Issues Stock Options
ACCESSWIRE - Thu Feb 20, 6:07PM CST
TORONTO, ONTARIO, February 20, 2014 - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that an aggregate of 567,460 incentive stock options have been granted to two directors of the Company and to a contractor of the Company. The 417,460 options issued to the directors are exercisable at $0.18 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The 150,000 options issued to the contractor are exercisable at $0.15 per share for five years from the date of grant, vest equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws. CardioComm Solutions Completes Technology Pilot in the Long-Term Patient Care Market with the HeartCheck(tm) ECG Monitor and SMART Monitoring ECG Service Technologies
ACCESSWIRE - Fri Feb 07, 8:25AM CST
Arrhythmia Surveillance Utilized HeartCheck(TM) Device and SMART Monitoring ECG Service Technologies
CardioComm Solutions Closes Second Tranche of Equity Financing; Company Remains on Track to Complete $1 Million in Financing in Q1 2014
ACCESSWIRE - Fri Jan 31, 8:01AM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
announced today it has closed the second tranche of its previously announced private placement equity financing. Under the financing, the Company issued 2,648,000 units at a price of $0.0675 per unit, for gross proceeds of $178,740. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.10. For further information regarding the financing, please see the Company's press release that was issued on January 9, 2014. The gross proceeds from the financing will be used for general working capital of the Company. The shares and warrants issued by the Company are subject to a four month hold period which expires on May 31, 2014. The Company also confirmed that it will continue its current private placement equity financing offer. CardioComm Solutions Executes Distribution and Co-Marketing Agreement to Promote HeartCheck(tm) PEN Sales and SMART Monitoring Services. SMART Monitoring Integration of Reka ECG...
ACCESSWIRE - Thu Jan 23, 4:08PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that it has completed a HeartCheck(TM) and SMART Monitoring distribution and co-marketing agreement ("Agreement" with Reka Health, Inc. (REKA), a US based company. REKA will promote sales of the HeartCheck(TM) PEN through their own, proprietary international distribution channels, including US-based accountable care organization ("ACO" patient portals. CardioComm Solutions Issues Correction with Respect to Closing First Tranche of Financing
ACCESSWIRE - Wed Jan 22, 6:19PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today issued the following correction to its press release dated January 21, 2014 respecting the closing of the first tranche of its ongoing private placement equity financing: Please note that in the first tranche the Company issued 1,622,222 units at a price of $0.0675 per unit, for gross proceeds of $109,500. CardioComm Solutions Secures $500,000 in GEMS(tm) 4 and GUAVA Software License Agreement. Licensing Deal Signals the Start of Sales of Windows 7 Compatible ECG Software Solutions
ACCESSWIRE - Wed Jan 22, 2:55PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that it has completed a software and source code licensing agreement ("SLA" for use of the Company's proprietary Global ECG Management Solution ("GEMS(TM)" and GUAVA ECG viewer by MD Primer Inc. ("MDP" . MDP is a clinical research and education organization enabling improvement in patient care through innovation. MDP is under the direction of Dr. Anatoly Langer, CardioComm Solutions' Chairman. As MDP is a related party of CardioComm Solutions, Dr. Langer abstained from voting on the SLA when it received board approval. The SLA is subject to approval by the TSX Venture Exchange. CardioComm Solutions Closes First Tranche of Equity Financing. Company Plans to Complete $1 Million in Financing in Q1 2014
ACCESSWIRE - Tue Jan 21, 8:10PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
announced today it had closed the first tranche of its previously announced private placement equity financing. Under the financing, the Company issued $1,622,222 units at a price of $0.0675 per unit, for gross proceeds of $109,500. Each unit was comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.10. For further information regarding the financing, please see the Company's press release that was issued on January 9, 2014. The gross proceeds from the financing will be used for general working capital of the Company. The shares and warrants issued by the Company are subject to a four month hold period which expires on May 21, 2014. The Company also confirmed that it will continue its current private placement equity financing offer. CardioComm Solutions Re-Prices Previously Announced Equity Financing
ACCESSWIRE - Thu Jan 09, 5:47PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that it has re-priced its previously announced equity financing. The Company will now be conducting a private placement equity financing under which it intends to issue 15,000,000 units at a price of $0.0675 per unit for gross proceeds of $1,012,500. Each unit will be comprised of one common share of the Company and one common share purchase warrant exercisable for two years for an additional share at a price of $0.10. The securities to be issued under the financing will be subject to a four month hold period. The terms of the financing are subject to the approval of the TSX Venture Exchange. Cardiocomm Solutions Appoints Industry Veteran As Vp Sales And Marketing To Build U.S. Based Patient Monitoring Software And Ecg Services Business
ACCESSWIRE - Wed Jan 08, 10:01AM CST
Former Executive of ScottCare, CardioNet and Lifewatch Corporation Set to Drive Sales of GEMS(TM) and Mobile Patient Monitoring Solutions into the U.S. Market
CardioComm Solutions Announces Equity Financing. Funding will be used as bridge financing to complete Q1 2014 objectives
ACCESSWIRE - Thu Dec 12, 12:53PM CST
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"
today announced that it will be conducting a non-brokered private placement equity financing under which it intends to issue between 4,166,667 to 8,333,334 units at a price of $0.12 per unit for gross proceeds of $500,000 to $1,000,000. Each unit will be comprised of one (1) common share of the Company and one (1) common share purchase warrant exercisable for two (2) years for an additional share at a price of $0.18. The securities to be issued under the financing will be subject to a four (4) month hold period. The terms of the financing are subject to the approval of the TSX Venture Exchange. CardioComm Solutions to Offer Free SMART Monitoring ECG Readings to HeartCheck(tm) Device Owners through GEMS Home in the United States. Free Cardiac Arrhythmia Surveillance Ava...
ACCESSWIRE - Tue Dec 10, 10:37AM CST
Toronto, Canada - CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or the "Company"
, a global medical provider of electrocardiogram ("ECG" acquisition and management software solutions, announced it shall be providing HeartCheckTM SMART Monitoring ECG services at no cost effective December 10, 2013 for its USA based customers who have been provided a HeartCheckTM device under a physician prescription. Medical Electronics - Global Trends, Estimates and Forecasts, 2011-2018
M2 - Fri Dec 06, 4:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7plqm/medical) has announced the addition of the "Medical Electronics - Global Trends, Estimates and Forecasts, 2011-2018" report to their offering. The Medical Electronics Market Is Expected To Reach US$372.4 Billion By 2018. Globally, medical therapeutics and imaging systems together account for approximately 52.9% of the market and are expected to support the medical electronics industry going forward. Geographical analysis shows that the highest Compounded Annual Growth Rate (CAGR) of 17.2% is anticipated from Asia-Pacific region during the analysis period, 2011-2018. Among the application sectors, monitoring & surgical systems account for the largest share of the entire market, driving a CAGR of 13.4% during the analysis period 2011-2018. Imaging Systems see as the fastest growing application with a forecast CAGR of approximately 16.9% by 2018. Along with the fast growth and rapid advancement in technology related to healthcare industry, the medical electronics expectations have increased innovatively for large numbers of incurable disease. Publication Overview The report reviews the latest medical electronics market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for electronics sector investments. The study reveals profitable investment strategies for electronics companies, business executives, product marketing managers, new business investors and many more in preferred locations. The report primarily focuses on: - Emerging Market Trends - Advancements in the Technological Space - Market Demand of the Segments (By-Region) - Key Growth Areas and Market Size - Region-Wise Demand Factor - Key Competitors Edge - Investment Strategies More than 1346 leading market players have been identified in electronics industry. 51 key companies are profiled. Applications Covered - Monitoring & Surgical Systems - Medical Therapeutics - Imaging Systems - Diagnostics Examples of Companies Mentioned - 3M Healthcare - Abbott Vascular Devices - Baxter International - Becton, Dickinson & Co. - Blueradios - C. R. Bard - Cactus Semiconductor - Cardiocomm Solutions - Cardiomems - Digirad Corporation - Medtronic - Monebo Technologies - Novadaq Technologies - Perkinelmer - Siemens Medical Solutions - St. Jude Medical - Fukuda Denshi - Heartware - IBM - Indraprastha Apollo Hospital - Panasonic Electric Works - Microports Medical - Nihon Kohden Corporation - Covidien - Dr?ger Medical Ag & Co. - F.Hoffmann-La Roche - Ge Healthcare - Philips Medical Systems - Siemens Group - Smith & Nephew For more information visit http://www.researchandmarkets.com/research/b7plqm/medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
CardioComm Solutions' HeartCheck (tm) Technologies to be Used in Canadian Parkinson's Research Study. Second CIHR and Industry Sponsored Study to Use HeartCheck (tm) and SMART ...
ACCESSWIRE - Thu Dec 05, 3:23PM CST
Toronto, Canada - CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or the "Company"
, a global medical provider of electrocardiogram ("ECG" acquisition and management software solutions, announced it shall be providing HeartCheckTM based ECG screening technologies to researchers from the Research Institute of the McGill University Health Centre (RI MUHC) and the Montreal General Hospital (Quebec, Canada). This research study, which will be funded by the Canadian Institutes of Health Research (CIHR) and the Webster Foundation, will evaluate the potential relationship between caffeine intake and improvements in motor symptoms of persons with Parkinson's disease ("PD" . Cardiocomm Solutions Completes Mobile Cardiac Telemetry Software Release for Raytel Cardiac Services
ACCESSWIRE - Mon Nov 25, 2:17PM CST
Raytel Cardiac Services will be the first to launch into the American MCT monitoring market using the CardioComm Solutions Wireless Arrhythmia Services Software
CardioComm Solutions' GEMS Home & SMART Monitoring Technologies Expanded To Support Prescription, HeartCheckTM Handheld ECG Devices
ACCESSWIRE - Tue Nov 12, 6:32PM CST
Rapid physician ECG interpretation services now available to patients, allied health care workers and physician groups.
CardioComm Solutions' HeartCheckTM ECG Monitoring Technologies for Atrial Fibrillation Screening to be Presented at the Canadian Stroke Congress
ACCESSWIRE - Wed Sep 18, 9:18AM CDT
Results from the Heart and Stroke Foundation "Be Pulse Aware" ECG Screening Campaign will be released during Vascular 2013
